Trials / Withdrawn
WithdrawnNCT05344365
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
An Open-label, Sequential Cohorts, Flexible Dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Iloperidone in Elderly Patients With Parkinson's Disease Psychosis (PDP)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with Parkinson's disease psychosis (PDP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iloperidone | oral tablet |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2023-11-01
- Completion
- 2023-11-01
- First posted
- 2022-04-25
- Last updated
- 2024-03-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05344365. Inclusion in this directory is not an endorsement.